Congratulations to SR One portfolio company Avenzo Therapeutics on the announcement of an exclusive option agreement with VelaVigo to support development efforts for a potential first-in-classbispecific antibody-drug conjugate (ADC) targeting multiple solid tumor types. Congrats also to Scott Lipman on his promotion to Chief Business Officer!? We're thrilled to work with forward-looking #portfoliocompanies like Avenzo and are pleased to welcome three new investors to the syndicate to close the Series A/A-1 financing. #AntibodyDrugConjugate #ADCs
Today marks an important step in our growth as we announce the closing of the final tranche of a Series A/A-1 #financing, bringing our total capital raised to $386M. Additionally, we entered an exclusive option agreement with VelaVigo to develop, manufacture & commercialize a potential first-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (#ADC) for multiple solid tumors, including metastatic urothelial #cancer.? ? Lastly, we are proud to share that Scott Lipman, MBA, has received the well-deserved promotion to Chief Business Officer. These significant milestones build on our continued momentum as we continue to build and advance a pipeline of best- or first-in-class #oncology therapies. Read the full press release here: https://bit.ly/3AMWkgs?